IP Library Granted Patent US 7,109,205
Granted Patent B2
US 7,109,205 · App. 10/602,275 · Granted Sep 19, 2006

Carboxylic acid derivatives, their preparation and use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,109,205
App. No.
10/602,275
Granted
Sep 19, 2006
Kind
B2
Abstract

Carboxylic acid derivatives where R–R 6 , X, Y and Z have the meanings stated in the description, and the preparation thereof, are described. The novel compounds are suitable for controlling diseases.

Claims (40)

1. A compound having the formula:

wherein:

X is CH;

Y is oxygen;

Z is oxygen;

R is CO 2 H;

R 2 is methyl;

R 3 is methyl;

R 4 is phenyl;

R 5 is phenyl; and

R 6 is methyl,

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein said compound is an optically active enantiomer.

3. The compound of claim 2 , wherein the enantiomer is the S enantiomer.

4. The compound of claim 3 , wherein the enantiomer is the pure form of the S enantiomer.

5. The compound of claim 2 , wherein the enantiomer is the R enantiomer.

6. The compound of claim 5 , wherein the enantiomer is the pure form of the R enantiomer.

7. A pharmaceutical composition comprising a compound having the formula:

wherein:

X is CH;

Y is oxygen;

Z is oxygen;

R is CO 2 H;

R 2 is methyl;

R 3 is methyl;

R 4 is phenyl;

R 5 is phenyl;

R 6 is methyl; or a

pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

8. The composition of claim 7 , wherein said composition is suitable for oral, parenteral, or nasopharyngeal delivery.

9. The composition of claim 7 , wherein the composition is in a solid form.

10. The composition of claim 7 , wherein the composition is in a liquid form.

11. The composition of claim 7 , wherein the composition is in the form of a tablet, capsule, powder, granule, suppository, solution, colloid, ointment, cream, vapor or spray.

12. The composition of claim 7 , wherein the carrier comprises a tablet binder, filler, preservative, tablet disintegrant, flow regulator, plasticizer, wetting agent, dispersant, emulsifier, solvent, release-slowing agent, antioxidant, or propellant gas.

13. The composition of claim 7 , wherein the compound is an optically active enantiomer.

14. The composition of claim 13 , wherein the enantiomer is the S enantiomer.

15. The composition of claim 14 , wherein the enantiomer is the pure form of the S enantiomer.

16. The composition of claim 13 , wherein the enantiomer is the R enantiomer.

17. The composition of claim 16 , wherein the enantiomer is the pure form of the R enantiomer.

18. The compound

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2014
From: ABBVIE DEUTSCHLAND GMBH & CO. KG
To: ROYALTY PHARMA COLLECTION TRUST
Reel/Frame 033776/0850 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2013
From: ABBOTT GMBH & CO KG
To: ABBVIE DEUTSCHLAND GMBH & CO KG
Reel/Frame 030688/0537 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2003
From: RIECHERS, HARTMUT; KLINGE, DAGMAR; AMBERG, WILHELM; KLING, ANDREAS; MULLER, STEFAN; BAUMANN, ERNST; RHEINHEIMER, JOACHIM; VOGELBACHER, UWE JOSEF; WERNET, WOLFGANG; UNGER, LILIANE; RASCHACK, MANFRED
To: ABBOTT GMBH & CO. KG
Reel/Frame 014778/0028 →